
Health Check 2025: A big year for tackling malaria
Dec 24, 2025
In this insightful discussion, James Tibenderana, Chief Executive at the Malaria Consortium, shares vital advancements in malaria control for 2025, including breakthroughs in vaccine rollout and new treatment strategies. Abdoulaye Djimdé, Professor of Parasitology, details the clinical success of a new drug, Ganaplacide-lumefantrine, and its unique mechanism against resistance. Ellie Sherrard-Smith explains the innovative passive spatial emanators designed for indoor mosquito control, highlighting their role in reducing malaria transmission. The stakes are high amid funding cuts affecting global health initiatives.
AI Snips
Chapters
Transcript
Episode notes
New Non-Artemisinin Drug: Ganlum
- Ganaplacide-lumefantrine (Ganlum) uses a non-artemisinin mechanism and showed >97% efficacy in phase III trials.
- It offers a transformative alternative especially where artemisinin partial resistance is rising.
Use Multiple First-Line Therapies
- Employ multiple first-line therapies rather than relying on a single antimalarial drug.
- Rotate or parallelize drugs to slow the emergence of resistance and preserve treatment efficacy.
Infant-Specific Drug Formulation
- A baby-specific dispersible artemisinin formulation (Baby Coatum/Riamet Baby) fills a dosing and palatability gap for infants under 4.5 kg.
- Tailored formulations reduce dosing errors and make safe treatment of the most vulnerable infants easier.


